LIFEVANTAGE CORP Current Liabilities
LIFEVANTAGE CORP (LFVN) had Current Liabilities of $20.23 million as of 2026-06-30, per its 10-K filed 2026-08-27.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:LiabilitiesCurrent · last filed 2026-08-27
- 2026-06-30: Liabilities, Current $20.23M.
- 2026-03-31: Liabilities, Current $20.10M.
- 2025-12-31: Liabilities, Current $19.01M.
- 2025-09-30: Liabilities, Current $18.83M.
| Period end | Liabilities, Current | Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $20.23M 10-K · filed 2026-08-27 | |
| 2026-03-31 | $20.10M 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $19.01M 10-Q · filed 2026-02-04 | |
| 2025-09-30 | $18.83M 10-Q · filed 2025-11-04 | |
| 2025-06-30 | $27.22M 10-K · filed 2026-08-27 | |
| 2025-03-31 | $32.58M 10-Q · filed 2025-05-06 | |
| 2024-12-31 | $27.55M 10-Q · filed 2025-02-05 | |
| 2024-09-30 | $22.07M 10-Q · filed 2024-10-29 | |
| 2024-06-30 | $22.31M 10-K · filed 2025-09-04 | |
| 2024-03-31 | $22.48M 10-Q · filed 2024-05-02 | |
| 2023-12-31 | $23.02M 10-Q · filed 2024-01-30 | |
| 2023-09-30 | $24.70M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $19.61M 10-K · filed 2024-08-28 | |
| 2023-03-31 | $21.40M 10-Q · filed 2023-05-04 | |
| 2022-12-31 | $23.33M 10-Q · filed 2023-02-02 | |
| 2022-09-30 | $22.77M 10-Q · filed 2022-11-02 | |
| 2022-06-30 | $25.73M 10-K · filed 2023-08-28 | |
| 2022-03-31 | $23.61M 10-Q · filed 2022-05-03 | |
| 2021-12-31 | $22.17M 10-Q · filed 2022-02-01 | |
| 2021-09-30 | $22.27M 10-Q · filed 2021-11-04 | |
| 2021-06-30 | $25.20M 10-K · filed 2022-08-23 | |
| 2021-03-31 | $22.28M 10-Q · filed 2021-04-29 | |
| 2020-12-31 | $22.45M 10-Q · filed 2021-02-02 | |
| 2020-09-30 | $22.02M 10-Q · filed 2020-11-03 | |
| 2020-06-30 | $25.02M 10-K · filed 2021-08-19 | |
| 2020-03-31 | $23.32M 10-Q · filed 2020-05-05 | |
| 2019-12-31 | $25.25M 10-Q · filed 2020-01-28 | |
| 2019-09-30 | $25.31M 10-Q · filed 2019-10-30 | |
| 2019-06-30 | $26.20M 10-K · filed 2020-08-18 | |
| 2019-03-31 | $27.48M 10-Q · filed 2019-05-01 | |
| 2018-12-31 | $28.76M 10-Q · filed 2019-02-04 | |
| 2018-09-30 | $23.59M 10-Q · filed 2018-11-01 | |
| 2018-06-30 | $23.80M 10-K · filed 2019-08-14 | |
| 2018-03-31 | $25.69M 10-Q · filed 2018-05-09 | |
| 2017-12-31 | $22.73M 10-Q · filed 2018-02-07 | |
| 2017-09-30 | $22.13M 10-Q · filed 2017-11-08 | |
| 2017-06-30 | $23.36M 10-K · filed 2018-08-15 | |
| 2017-03-31 | $24.91M 10-Q · filed 2017-05-10 | |
| 2016-12-31 | $23.54M 10-Q · filed 2017-02-08 | |
| 2016-09-30 | $26.71M 10-Q · filed 2016-12-12 | |
| 2016-06-30 | $30.63M 10-K · filed 2017-09-07 | $28.55M 10-K · filed 2016-12-12 |
| 2016-03-31 | $25.30M 10-Q/A · filed 2016-07-19 | |
| 2015-12-31 | $34.82M 10-Q · filed 2016-02-09 | |
| 2015-09-30 | $27.95M 10-Q · filed 2015-11-04 | |
| 2015-06-30 | $25.86M 10-K · filed 2016-12-12 | |
| 2015-03-31 | $24.80M 10-Q · filed 2015-05-06 | |
| 2014-12-31 | $21.56M 10-Q · filed 2015-02-04 | |
| 2014-09-30 | $23.37M 10-Q · filed 2014-11-06 | |
| 2014-06-30 | $22.70M 10-K · filed 2015-09-01 | |
| 2014-03-31 | $25.30M 10-Q · filed 2014-05-06 | |
| 2013-12-31 | $21.92M 10-Q · filed 2014-02-06 | |
| 2013-09-30 | $18.43M 10-Q · filed 2013-11-07 | |
| 2013-06-30 | $20.57M 10-K · filed 2014-09-10 | |
| 2013-03-31 | $18.58M 10-Q · filed 2013-05-09 | |
| 2012-12-31 | $18.74M 10-Q · filed 2013-02-07 | |
| 2012-09-30 | $15.50M 10-Q · filed 2012-11-08 | |
| 2012-06-30 | $16.03M 10-K · filed 2013-09-12 | $16.03M 10-K · filed 2012-09-10 |
| 2012-03-31 | $10.77M 10-Q · filed 2012-05-15 | |
| 2011-12-31 | $15.30M 10-Q · filed 2012-02-14 | |
| 2011-09-30 | $14.01M 10-Q · filed 2011-11-14 | |
| 2011-06-30 | $13.38M 10-K · filed 2012-09-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |